Assessing the risk of osteonecrosis of the jaw due to bisphosphonate therapy in the secondary prevention of osteoporotic fractures

Giuseppina Campisi, Mazzaglia, Vaccheri, Carle, Gregori, Corrao, Maria Luisa Brandi, Vittorio Fusco, Staniscia, Lapi, Sturkenboom, Vestri, Caputi, Di Bari, Cipriani

Risultato della ricerca: Article

26 Citazioni (Scopus)

Abstract

here is evidence that the use oral bisphosphonates can lead to osteronecrosis of the jaws (ONJ). Although the occurrence of ONJ appears rare among oral bisphosphonates (BPs) users, it is important to know that it exists and can be opportunely minimized. Introduction: The purpose of this study is to evaluate the association between BPs prescribed for the secondary prevention of osteoporotic fractures and the occurrence of ONJ. Methods: An Italian record linkage claims database with a target population of around 18 million individuals (6 million over 55 years of age) constituted the data source. We conducted a nested case-control study within a cohort of individuals aged 55+ years old, who were discharged from hospitals with a primary diagnosis of incident osteoporotic fracture. The date related to the discharge diagnosis of ONJ was the index date. Conditional logistic regression for matched data was fitted to estimate the odds ratio (OR) along with 95 % confidence intervals (95 % CI) for the likely association between use of BPs and the risk of ONJ. Results: Any one of the 61 ascertained cases of ONJ (incidence rate, 36.6 per 100,000 person-years) was matched to 20 controls for a total of 1120 controls. When the exposure to BPs was modeled according to recency (i.e., exposure time window prior to the index date) of use, the adjusted OR (95 % CI) for current users was 2.8 (1.3-5.9) against never users. The cumulative use of BPs has shown to increase the incidence of ONJ among patients with primary osteoporotic fractures, although not statistically significant risk has been observed. Conclusions: Although the risk of BP-related ONJ appears low in non-oncological indications, it is important to be aware that it exists and to know how it may be predicted and possibly minimized.
Lingua originaleEnglish
pagine (da-a)697-705
Numero di pagine9
RivistaOsteoporosis International
Volume24
Stato di pubblicazionePublished - 2013

Fingerprint

Osteoporotic Fractures
Osteonecrosis
Diphosphonates
Secondary Prevention
Jaw
Therapeutics
Odds Ratio
Confidence Intervals
Health Services Needs and Demand
Information Storage and Retrieval
Incidence
Case-Control Studies
Logistic Models
Databases

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism

Cita questo

Assessing the risk of osteonecrosis of the jaw due to bisphosphonate therapy in the secondary prevention of osteoporotic fractures. / Campisi, Giuseppina; Mazzaglia; Vaccheri; Carle; Gregori; Corrao; Brandi, Maria Luisa; Fusco, Vittorio; Staniscia; Lapi; Sturkenboom; Vestri; Caputi; Di Bari; Cipriani.

In: Osteoporosis International, Vol. 24, 2013, pag. 697-705.

Risultato della ricerca: Article

Campisi, G, Mazzaglia, Vaccheri, Carle, Gregori, Corrao, Brandi, ML, Fusco, V, Staniscia, Lapi, Sturkenboom, Vestri, Caputi, Di Bari & Cipriani 2013, 'Assessing the risk of osteonecrosis of the jaw due to bisphosphonate therapy in the secondary prevention of osteoporotic fractures', Osteoporosis International, vol. 24, pagg. 697-705.
Campisi, Giuseppina ; Mazzaglia ; Vaccheri ; Carle ; Gregori ; Corrao ; Brandi, Maria Luisa ; Fusco, Vittorio ; Staniscia ; Lapi ; Sturkenboom ; Vestri ; Caputi ; Di Bari ; Cipriani. / Assessing the risk of osteonecrosis of the jaw due to bisphosphonate therapy in the secondary prevention of osteoporotic fractures. In: Osteoporosis International. 2013 ; Vol. 24. pagg. 697-705.
@article{95b2deb63d524f538e091ee16fce077c,
title = "Assessing the risk of osteonecrosis of the jaw due to bisphosphonate therapy in the secondary prevention of osteoporotic fractures",
abstract = "here is evidence that the use oral bisphosphonates can lead to osteronecrosis of the jaws (ONJ). Although the occurrence of ONJ appears rare among oral bisphosphonates (BPs) users, it is important to know that it exists and can be opportunely minimized. Introduction: The purpose of this study is to evaluate the association between BPs prescribed for the secondary prevention of osteoporotic fractures and the occurrence of ONJ. Methods: An Italian record linkage claims database with a target population of around 18 million individuals (6 million over 55 years of age) constituted the data source. We conducted a nested case-control study within a cohort of individuals aged 55+ years old, who were discharged from hospitals with a primary diagnosis of incident osteoporotic fracture. The date related to the discharge diagnosis of ONJ was the index date. Conditional logistic regression for matched data was fitted to estimate the odds ratio (OR) along with 95 {\%} confidence intervals (95 {\%} CI) for the likely association between use of BPs and the risk of ONJ. Results: Any one of the 61 ascertained cases of ONJ (incidence rate, 36.6 per 100,000 person-years) was matched to 20 controls for a total of 1120 controls. When the exposure to BPs was modeled according to recency (i.e., exposure time window prior to the index date) of use, the adjusted OR (95 {\%} CI) for current users was 2.8 (1.3-5.9) against never users. The cumulative use of BPs has shown to increase the incidence of ONJ among patients with primary osteoporotic fractures, although not statistically significant risk has been observed. Conclusions: Although the risk of BP-related ONJ appears low in non-oncological indications, it is important to be aware that it exists and to know how it may be predicted and possibly minimized.",
author = "Giuseppina Campisi and Mazzaglia and Vaccheri and Carle and Gregori and Corrao and Brandi, {Maria Luisa} and Vittorio Fusco and Staniscia and Lapi and Sturkenboom and Vestri and Caputi and {Di Bari} and Cipriani",
year = "2013",
language = "English",
volume = "24",
pages = "697--705",
journal = "Osteoporosis International",
issn = "0937-941X",
publisher = "Springer London",

}

TY - JOUR

T1 - Assessing the risk of osteonecrosis of the jaw due to bisphosphonate therapy in the secondary prevention of osteoporotic fractures

AU - Campisi, Giuseppina

AU - Mazzaglia, null

AU - Vaccheri, null

AU - Carle, null

AU - Gregori, null

AU - Corrao, null

AU - Brandi, Maria Luisa

AU - Fusco, Vittorio

AU - Staniscia, null

AU - Lapi, null

AU - Sturkenboom, null

AU - Vestri, null

AU - Caputi, null

AU - Di Bari, null

AU - Cipriani, null

PY - 2013

Y1 - 2013

N2 - here is evidence that the use oral bisphosphonates can lead to osteronecrosis of the jaws (ONJ). Although the occurrence of ONJ appears rare among oral bisphosphonates (BPs) users, it is important to know that it exists and can be opportunely minimized. Introduction: The purpose of this study is to evaluate the association between BPs prescribed for the secondary prevention of osteoporotic fractures and the occurrence of ONJ. Methods: An Italian record linkage claims database with a target population of around 18 million individuals (6 million over 55 years of age) constituted the data source. We conducted a nested case-control study within a cohort of individuals aged 55+ years old, who were discharged from hospitals with a primary diagnosis of incident osteoporotic fracture. The date related to the discharge diagnosis of ONJ was the index date. Conditional logistic regression for matched data was fitted to estimate the odds ratio (OR) along with 95 % confidence intervals (95 % CI) for the likely association between use of BPs and the risk of ONJ. Results: Any one of the 61 ascertained cases of ONJ (incidence rate, 36.6 per 100,000 person-years) was matched to 20 controls for a total of 1120 controls. When the exposure to BPs was modeled according to recency (i.e., exposure time window prior to the index date) of use, the adjusted OR (95 % CI) for current users was 2.8 (1.3-5.9) against never users. The cumulative use of BPs has shown to increase the incidence of ONJ among patients with primary osteoporotic fractures, although not statistically significant risk has been observed. Conclusions: Although the risk of BP-related ONJ appears low in non-oncological indications, it is important to be aware that it exists and to know how it may be predicted and possibly minimized.

AB - here is evidence that the use oral bisphosphonates can lead to osteronecrosis of the jaws (ONJ). Although the occurrence of ONJ appears rare among oral bisphosphonates (BPs) users, it is important to know that it exists and can be opportunely minimized. Introduction: The purpose of this study is to evaluate the association between BPs prescribed for the secondary prevention of osteoporotic fractures and the occurrence of ONJ. Methods: An Italian record linkage claims database with a target population of around 18 million individuals (6 million over 55 years of age) constituted the data source. We conducted a nested case-control study within a cohort of individuals aged 55+ years old, who were discharged from hospitals with a primary diagnosis of incident osteoporotic fracture. The date related to the discharge diagnosis of ONJ was the index date. Conditional logistic regression for matched data was fitted to estimate the odds ratio (OR) along with 95 % confidence intervals (95 % CI) for the likely association between use of BPs and the risk of ONJ. Results: Any one of the 61 ascertained cases of ONJ (incidence rate, 36.6 per 100,000 person-years) was matched to 20 controls for a total of 1120 controls. When the exposure to BPs was modeled according to recency (i.e., exposure time window prior to the index date) of use, the adjusted OR (95 % CI) for current users was 2.8 (1.3-5.9) against never users. The cumulative use of BPs has shown to increase the incidence of ONJ among patients with primary osteoporotic fractures, although not statistically significant risk has been observed. Conclusions: Although the risk of BP-related ONJ appears low in non-oncological indications, it is important to be aware that it exists and to know how it may be predicted and possibly minimized.

UR - http://hdl.handle.net/10447/72609

M3 - Article

VL - 24

SP - 697

EP - 705

JO - Osteoporosis International

JF - Osteoporosis International

SN - 0937-941X

ER -